The FDA approved the PCA3 urine test in February 2012 to be used in conjunction with other patient information to help clinicians determine if men who have had a previous negative prostate biopsy should undergo a repeat biopsy.

Although PCA3 has lower sensitivity than PSA, it has higher specificity for prostate cancer as well as superior positive and negative predictive values. Some 20%-40% of men who had initial negative biopsy are found to have an abnormal biopsy on repeat testing.

Renal & Urology News would like to know how urologists have embraced the PCA3 urine test, so please answer the following poll question:

Continue Reading

Leave a comment below to explain your choice.

Topics:

Prostate Cancer